ARS Pharma Reports Strong Neffy Revenue Growth, Key Commercial Milestones, and Pipeline Progress
SPRY sits 20% above its 52-week low of $6.66.
Summary
ARS Pharmaceuticals reported strong Q1 2026 revenue for Neffy, alongside critical updates on market access, international approvals, and clinical pipeline advancement, reinforcing its commercial strategy and future growth prospects.
Key Events · Earnings and Guidance · SPRY
-
Strong Q1 2026 Revenue Growth
Total revenue reached $22.7 million, with $17.5 million from U.S. Neffy sales, demonstrating strong commercial momentum.
-
CVS Caremark Formulary Progress
A proposal to CVS Caremark for Neffy's commercial formulary is in the final approval stages, targeting a July 1, 2026 effective date, which is a major step for market access.
-
Expanded Regulatory Approvals
Neffy received Health Canada approval and EU marketing authorization, significantly broadening its international market reach.
-
Advanced Clinical Pipeline
The Phase 2b study for chronic spontaneous urticaria (CSU) is fully enrolled for its interim analysis, with results expected in Q4 2026, advancing a potential new blockbuster indication.
Analysis · SPRY · Life Sciences
This 8-K furnishes the Q1 2026 financial results and a corporate presentation, detailing significant commercial and regulatory advancements for Neffy. The company reported robust revenue growth for Neffy and provided a reassuring cash runway. Crucially, ARS Pharma announced that its proposal to CVS Caremark for formulary inclusion is in the final stages, which could significantly expand market access. Additionally, Neffy received Health Canada approval and EU marketing authorization, and the Phase 2b CSU study is on track for a Q4 2026 readout, indicating strong pipeline progression.
At the time of this filing, SPRY was trading at $7.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $788.4M. The 52-week trading range was $6.66 to $18.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.